Home

KEN TAKANASHI

CIK 1657768 · last filed 2026-08-13

KEN TAKANASHI is a corporate insider who has filed 20 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing shows the insider sold $23.2K of WVE on Aug 13, 2026. Across all open-market trades the lifetime net is +$27.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $44.2M across reported positions. 2 SEC filings were submitted jointly with Shin Nippon Biomedical Laboratories, Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$44.19M

Companies

2

Total Filings

20

Lifetime Open-Market Net

$27.50M

Filer Profile

Reported Address
C/O WAVE LIFE SCIENCES LTD.
733 CONCORD AVE.
CAMBRIDGE, MA 02138
Related Filers
Shin Nippon Biomedical Laboratories, Ltd. — 2 joint filings, latest 2015-11-18
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
WVE Director 9,626,487 $4.59 $44.19M $3.93M 14 2026-08-13
Satsuma Pharmaceuticals, Inc. (STSA) Delisted Director 24,847,694 $1.10 $27.33M $23.57M 6 2023-06-08

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-13 WVE Sell (S) −3,864 -$23.2K EDGAR
2026-03-26 WVE Conv (C) +3,901,348 $0 EDGAR
2025-08-13 WVE Grant (A) +12,700 $0 EDGAR
2025-08-07 WVE Sell (S) −4,872 -$42.6K EDGAR
2024-08-14 WVE Grant (A) +16,115 $0 EDGAR
2023-08-09 WVE Grant (A) — $0 EDGAR
2023-06-08 Satsuma Pharmaceuticals, Inc. (STSA) Delisted Mixed +22,053,581 $20.07M EDGAR
2022-12-09 Satsuma Pharmaceuticals, Inc. (STSA) Delisted Grant (A) — $0 EDGAR
2022-08-17 WVE Grant (A) — $0 EDGAR
2022-06-07 Satsuma Pharmaceuticals, Inc. (STSA) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.